Daiichi Sankyo Co 株価情報 (OTC: DSNKY)

最新ニュース Daiichi Sankyo Co (OTC:DSNKY) 株価情報

DAIICHI SANKYO

Daiichi Sankyo Co

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

DAIICHI SANKYO S/ADR by Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co Ltd

Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript

AstraZeneca, Daiichi file for FDA accelerated approval of Dato-DXd

AstraZeneca raised to neutral at UBS despite China headwinds

Franklin International Growth Fund Q3 2024 Commentary

AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe

AstraZeneca gets FDA breakthrough therapy status for Dato-DXd

AstraZeneca, Daiichi pull EU marketing application for lung cancer drug, Dato-DXd

Here are Morgan Stanley's key oncology catalysts for 2025

High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower

AstraZeneca, Daiichi Sankyo antibody-drug conjugate Dato-DXd gains FDA nod

AKESF

ARVN

AZNCF

BNTX

CEVMF

CEVMY

CYBR

DISPF

DSCSY

DSDVF

DSDVY

DSKYF

DSNKY

EVOTF

EXPGF

EXPGY

GILD

GMAB

GNMSF

ICGUF

KXSCF

MELI

MRNA

PMMAF

PUMSY

RCUS

REGN

RHHBF

RHHBY

SHOP

SKFOF

SMMT

SXYAY

Press Releases

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

CGEN

GRAL

TYO:4568

Comments

Daiichi Sankyo Co

ニュース

最新ニュース Daiichi Sankyo Co (OTC:DSNKY) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル